Overview

GEMOX: Oxaliplatin in Pancreatic Cancer

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Primary objective: - To evaluate overall response rate (based on RECIST criterion) Secondary objective: - To evaluate time to progression, clinical benefit, quality of life and safety

Phase:

Phase 2

Details

Lead Sponsor:

Sanofi

Treatments:

Oxaliplatin